ong term treatment study of 0.02% STN1013900 ophthalmic solution alone or in combination with either 0.005% Latanoprost ophthalmic solution, or 0.5%Timolol ophthalmic solution in subjects with open angle glaucoma or ocular hypertensio
- Conditions
- POAG, NTG, pseudoexfoliative glaucoma, pigmentary glaucoma or OHT
- Registration Number
- JPRN-jRCT2031210125
- Lead Sponsor
- Sakamoto Kayoko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
20 years of age or older
Diagnosis of POAG, NTG, pseudoexfoliative glaucoma, pigmentary glaucoma or OHT in both eyes
Best-corrected visual acuity (BCVA) +0.7 log MAR or better (>= 20/100 Snellen or >= 0.20 in decimal unit) in each eye
Willingness and ability to give signed informed consent and follow study instructions
Ophthalmic:
Clinically significant ocular disease
History of angle closure glaucoma, or narrow angles
Previous glaucoma intraocular surgery
Refractive surgery in either eye
Ocular trauma
Ocular infection
Any corneal disease
Known hypersensitivity to any component of the study drugs, or to topical anesthetic
Systemic:
Clinically significant systemic disease
Participation in any investigational study within 30 days prior to screening
Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method